Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

COVID-19 Clinical Trial

— RCT  

Official title:

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04344444
• Other study ID #: COVID 2020-001
• Status: Terminated
• Phase: Phase 3
• Start date: April 13, 2020
• Est. completion date: January 5, 2022

Study information

• Verified date: August 2020
• Source: LCMC Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.

Description:

This is a phase 3 study.

Primary Objective:

• To evaluate clinical outcomes in patients with suspected or confirmed COVID-19 with early moderate to severe disease in a randomized controlled trial.

Secondary Objectives:

• To evaluate quantitative viral load over time

• To evaluate length of hospital stay and days in ICU

• To evaluate toxicity of the treatment options

• To evaluate rate of readmission after hospital discharge

• To evaluate duration of clinical symptoms

Arm A:

Control Arm - Supportive Care Only

Arm B:

Hydroxychloroquine 400 mg po bid on Day 1 Hydroxychloroquine 200 mg po bid Days 2 through 5

Arm C:

Hydroxychloroquine as in Arm B AND Azithromycin 500 mg po on Day 1 Azithromycin 250 mg po days 2 through 5

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: January 5, 2022
• Est. primary completion date: April 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Age greater than 18 years

• Positive SARS-CoV-2 testing or consistent clinical syndrome (based on clinical picture e.g. characteristic infiltrates on chest x-ray, laboratory findings, and with agreement by two physicians) in patients under investigation (PUIs).

• Onset of symptoms < 7 days from date of enrollment

• Oxygen saturation of >94% on room air with defined risk factors (Table 1) consistent with moderate disease OR oxygen saturation of < 94% on room air consistent with severe disease

• Ability and willingness to comply with study procedures

Exclusion Criteria:

• QTc greater than 450 milliseconds on screening EKG

• Pregnant or lactating women

• Inability to take oral pills or inability to use a feeding tube

• Inability to obtain informed consent either from the patient or from the next of kin if patient is incapacitated. For the purpose of this study obtaining a verbal consent from a family member on the phone with a witness will be considered acceptable since there is a 'no visitor' policy in force at hospitals.

• Patients requiring ICU level care

• use of azithromycin or hydroxychloroquine within 30 days prior to admission

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• Hydroxychloroquine
tablets provided as described in Arm B
• Azithromycin
tablets provided as described in Arm C

Locations

Country	Name	City	State
United States	University Medical Center New Orleans	New Orleans	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
LCMC Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Most severe outcome	ordinal outcome of most severe a patient experienced after inpatient admission	5 days